Objective Lack of effective therapies remains a problem in the treatment of oral squamous
cell carcinoma (OSCC), especially in patients with advanced tumors. OSCC development is …

The CDK4/6 inhibitor palbociclib reduces tumor growth by decreasing retinoblastoma (RB)
protein phosphorylation and inducing cell cycle arrest at the G1/S phase transition …

The loss of p16 is a signature event in Human Papilloma Virus (HPV)-negative head and
neck squamous cell carcinoma (HNSCC) that leads to increased Cyclin Dependent Kinase …

Cell-cycle pathway impairments resulting in CDK4 and 6 activation are frequently observed
in human papillomavirus (HPV)-negative squamous cell carcinoma of the head and neck …

Background/purpose Palbociclib is an FDA-approved cyclin-dependent kinase (CDK) 4/6
inhibitor that has been clinically proven to be effective in breast cancer. However, its use in …

Background Palbociclib is a selective inhibitor of CDK4/6 approved in metastatic breast
cancer as well as evidence of activity in malignancies with CDK4-amplifications. Extensive …

Abstract Background: Combination of CDK4/6 inhibitors and endocrine therapy has been
shown to improve clinical outcome in advanced estrogen receptor-positive (ER+) breast …

Background Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor),
Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal …

Palbociclib is a specific inhibitor of CDK4/6 and has been shown to provide a survival
benefit in hormone receptor-positive advanced breast cancer. TCGA database reported that …

Activating alterations in PIK3CA, the gene coding for the catalytic subunit of
phosphoinositide-3-kinase (PI3K), are prevalent in head and neck squamous cell carcinoma …